Surveillance of Ocular Surface Flora (SURFACE)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Scheduled to undergo cataract surgery
- Able to provide written informed consent
Exclusion Criteria:
- NSAID in the eye to be swabbed within the past 30 days
- Topical anesthetic, topical antibiotic or antiseptic, or dilating drops in the eye to the swabbed within the past 7 days
- Over-the-counter artificial tear drops or astringent /redness reliever drops (e.g., Visine®, Clear eyes® in the eye to be swabbed on the day of trial
- History of conjunctivitis or any ocular infection within the past 3 months
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
All Patients Receiving Cataract Surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Eyelid
Time Frame: Baseline
|
Percentage of staphylococcus epidermidis species susceptible and resistant to oxacillin on the eyelid.
The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints.
MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation.
For Staphylococcus epidermidis, the oxacillin MIC breakpoints were <= 0.25 ug/ml (susceptible) and >= 0.50 ug/ml (resistant).
|
Baseline
|
|
Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Conjunctiva
Time Frame: Baseline
|
Percentage of staphylococcus epidermidis species susceptible and resistant to oxacillin on the conjunctiva .
The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints.
MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation.
For Staphylococcus epidermidis, the oxacillin MIC breakpoints were <= 0.25 ug/ml (susceptible) and >= 0.50 ug/ml (resistant).
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Eyelid
Time Frame: Baseline
|
Percentage of staphylococcus aureus species susceptible and resistant to oxacillin on the eyelid.
The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints.
MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation.
For Staphylococcus aureus, the oxacillin MIC breakpoints were <= 2 ug/ml (susceptible) and >= 4 ug/ml (resistant).
|
Baseline
|
|
Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Conjunctiva
Time Frame: Baseline
|
Percentage of staphylococcus aureus species susceptible and resistant to oxacillin on the conjunctiva.
The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints.
MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation.
For Staphylococcus aureus, the oxacillin MIC breakpoints were <= 2 ug/ml (susceptible) and >= 4 ug/ml (resistant).
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MA-Zymar-08-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.